Impact of subthalamic nucleus stimulation on young-onset Parkinson's disease

Neuromodulation

Volumn 13, Issue 1, 2010, Pages 10-16

  Otaka, Toshiharu ^a,b   Oshima, Hideki ^a,b   Katayama, Yoichi ^a,b   Kano, Toshikazu ^b   Kobayashi, Kazutaka ^b   Suzuki, Yutaka ^b   Fukaya, Chikashi ^a,b   Yamamoto, Takamitsu ^a,b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Brain stimulation; Neuromodulation; Parkinson's disease; Subthalamic nucleus; Young onset

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; ONSET AGE; PARKINSON DISEASE; RATING SCALE; SUBTHALAMIC NUCLEUS; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 74049152292     PISSN: 10947159     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2009.00248.x     Document Type: Article

References (32)

1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967 17 : 427 442.
2. Barbeau A, Pourcher E. New data on the genetics of Parkinson's disease. Can J Neurol Sci 1982 9 : 53 60.
3. Yokochi M. Effects and side effects of levodopa in parkinsonism: results of a collaborative study. (2) The relationship between the age of the onset and therapeutic effects. Rinsho Shinkeigaku 1976 16 : 871 873 in Japanese)
4. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991 41 : 380 384.
5. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991 41 : 202 205.
6. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 1998 13 : 885 894.
7. Kumar R, Lozano AM, Kim YJ et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998 51 : 850 855. (Pubitemid 28449271)
8. Limousin P, Krack P, Pollak P et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998 339 : 1105 1111. (Pubitemid 28465758)
9. Katayama Y, Kasai M, Oshima H et al. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients. J Neurosurg 2001 95 : 213 221.
10. Limousin P, Pollak P, Hoffmann D, Benazzouz A, Perret JE, Benabid AL. Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients. Mov Disord 1996 11 : 231 235.
11. Krack P, Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. From off-period dystonia to peak-dose chorea: the clinical spectrum of varying subthalamic nucleus activity. Brain 1999 122 : 1133 1146.
12. Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999 53 : 85 90.
13. Charles PD, Blercom NV, Krack P et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002 59 : 932 934.
14. Walter ML, Houeto JL, Tezenas du Montcel S et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002 125 : 575 583.
15. Krack P, Pollak P, Limousin P et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998 121 : 451 457. (Pubitemid 28116342)
16. Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In : Fahn S, Marsden CD, Goldstein M et al., eds. Recent developments in Parkinson's disease. New Zealand : Macmillan Health Care Information, 1987 : 153 163.
17. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997 337 : 1036 1042.
18. Goetz CG, Stebbins GT, Shale HM et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994 9 : 390 394.
19. Fahn S, Calne DB. Considerations in the management of parkinsonism. Neurology 1978 28 : 5 7.
20. Graham DG, Tiffany SM, Vogel FS. The toxicity of melanin precursors. J Invest Dermatol 1978 70 : 113 116.
21. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978 273 : 59 61.
22. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979 29 : 1253 1260.
23. Reches A, Tietler J, Lavy S. Parkinsonism due to lithium carbonate poisoning. Arch Neurol 1981 38 : 471.
24. Melamed E, Globus M, Friedlender E, Rosenthal J. Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections. Neurology 1983 33 : 950 953.
25. De Jong GJ, Meerwaldt JD, Schmitz PI. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987 22 : 4 7.
26. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease. Neurology 1987 37 : 826 828.
27. Hely MA, Morris JGL, Reid WGL. The Sydney multicenter study of Parkinson's disease: a randomized, prospective, five-year study comparing low-dose bromocriptine with low-dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994 57 : 903 910.
28. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's: a five year follow up. J Neurol Neurosurg Psychiatry 1994 57 : 1034 1038.
29. Przuntek H, Welzel D, Gerlach M et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects: long-term results of the PRADO study. J Neural Transm Gen Sect 1996 103 : n699 n715.
30. Rinne UK, Bracco F, Chouza C et al. Cabergoline in the treatment of early Parkinson's disease. Neurology 1997 48 : 363 368.
31. Rinne UK, Bracco F, Chouza C et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Drugs 1998 55 (Suppl. 1 23 30.
32. Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003 349 : 1925 1934. (Pubitemid 37409709)